Deans' stroke musings: EBS Reports That Its NEXT WAVE(TM) Brain Stimulation Device Expanded the Visual Field by a Mean Average of 24% in a Clinical Study of 82 Patients with Impaired Vision Caused by Optic Nerve Neuropathy or Stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, June 5, 2013

EBS Reports That Its NEXT WAVE(TM) Brain Stimulation Device Expanded the Visual Field by a Mean Average of 24% in a Clinical Study of 82 Patients with Impaired Vision Caused by Optic Nerve Neuropathy or Stroke

Contact if interested.
http://online.wsj.com/article/PR-CO-20130604-905592.html?mod=googlenews_wsj
EBS Technologies GmbH, an emerging medical device company developing the revolutionary NEXT WAVE(TM) brain stimulation platform for treatment of vision deficits caused by neurological disorders, announced today the results of a multi-center, 82-patient clinical trial of its NEXT WAVE(TM) brain stimulation device.
About one-half of the clinical trial patients were given a 40-minute treatment protocol for 10 consecutive days with the NEXT WAVE(TM) device. With a mean increase of 24%, NEXT WAVE(TM)-treated patients showed significantly better improvements in stimulation of their total visual field compared to patients in the control group, which did not receive NEXT WAVE(TM) stimulation. All patients had vision impairment lasting at least six months prior to the clinical trial and had exhausted all standard therapeutic options to improve their vision.
"There is a huge unmet clinical need for the treatment of vision impairment caused by a variety of different neurological disorders, such as neuropathy of the optic nerve, brain injury or stroke. For example, stroke alone is the world's third-leading cause of death as well as the leading cause of serious, long-term disability. There are more than 10.4 million stroke survivors with long-term disability in Europe and the U.S. Three out of five of these disabled persons are potentially treatable with our NEXT WAVE(TM) therapy once we commence commercialization," said Ulf Pommerening, CEO of EBS Technologies.
"We look forward to expanding the scientific evidence for the efficacy of our NEXT WAVE(TM) approach, especially in stroke patients, in an expanded clinical trial that will commence imminently," said Pommerening.